

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
*(amounts in thousands, except per share data)*

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2024	2023	2024	2023
Revenue from government contract	\$ 301	\$ -	\$ 301	\$ -
Operating expenses:				
Research and development	4,277	4,720	8,703	7,539
General and administrative	1,086	1,459	2,543	2,910
	<u>5,363</u>	<u>6,179</u>	<u>11,246</u>	<u>10,449</u>
Loss from operations	(5,062)	(6,179)	(10,945)	(10,449)
Other income (expense)	(2)	251	31	484
Net loss	<u>\$ (5,064)</u>	<u>\$ (5,928)</u>	<u>\$ (10,914)</u>	<u>\$ (9,965)</u>
Loss per common share	<u>\$ (1.99)</u>	<u>\$ (3.79)</u>	<u>\$ (4.68)</u>	<u>\$ (5.66)</u>

**Condensed Consolidated Balance Sheet Information**  
*(amounts in thousands, except common share information)*

	June 30, 2024	December 31, 2023
Assets		
Cash and cash equivalents	\$ 1,562	\$ 6,453
Other current assets	2,282	1,433
Total current assets	<u>3,844</u>	<u>7,886</u>
Property and other assets	251	1,397
Total assets	<u>\$ 4,095</u>	<u>\$ 9,283</u>
Liabilities and stockholders' equity (deficit)		
Total liabilities	\$ 6,404	\$ 3,520
Stockholders' equity (deficit)	<u>(2,309)</u>	<u>5,763</u>
Total liabilities and stockholders' equity (deficit)	<u>\$ 4,095</u>	<u>\$ 9,283</u>
Common shares outstanding	4,178,700	1,977,152